Related Experiment Video
Updated: May 30, 2025
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic
Rafael Madero-Marroquin1, Ryan W Hunter2, Caner Saygin1
1Department of Medicine, Section of Hematology/Oncology University of Chicago Chicago Illinois USA.
Background:
CD58 loss has been described as a mechanism of resistance to blinatumomab and chimeric antigen receptor T-cell therapy, functioning as a modulator of response to T-cell activation.
Methods:
Using flow cytometry, we evaluated the impact of CD58 mean fluorescence intensity (MFI) on the probability of achieving measurable residual disease (MRD) negativity in patients with B-cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin (InO).
Results:
The odds ratio of achieving MRD negativity was 1.03 for every 1000 unit increase in CD58 MFI.
Conclusion:
Our results suggest that MRD negativity rates after InO are high, regardless of the intensity of CD58 expression.
